Compare Citius Pharmaceuticals Inc (CTXR) vs Raytheon Technologies Corp (RTX) Price & Performance

CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.

Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.

RTX trades at $193.39, down 1.3% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $1.78 exceeding expectations of $1.51. Revenue grew to $88.60 billion in 2025, and net income margin improved to 8.03%. Recent contract wins, including a $515 million U.S. Navy radar award announced June 3, 2026, underscore its defense sector strength.

Outlook remains positive given earnings momentum and defense budget tailwinds, but valuation at a P/E of 36.85 poses a risk if growth slows. Analyst consensus price target of $213.00 suggests 10% upside, with no sell ratings among 26 coverage firms. Key risks include execution on production targets and geopolitical shifts affecting defense spending.